Targeting of YKL-40 as a Protumor in Personalized Medicine: A New Dimension in Disease Understanding
Since antibodies against YKL-40 can inhibit tumor angiogenesis and cancer progression, it can be suggested as an attractive candidate for chemical cancer therapy and immunomodulation.
Authors
- Iqra Saleem
- Hebatallah Ahmed Mohamed Moustafa (ORCID: https://orcid.org/0000-0003-4530-406X)
- Asmat Ullah (ORCID: https://orcid.org/0000-0002-6572-1242)
- Ahmed Sohaib (ORCID: https://orcid.org/0000-0002-6375-7831)
Institutions
- Shaikh Zayed Medical College and Hospital (PK)
- Superior University (PK)
- Zhejiang Provincial People's Hospital (CN)
- Badr University in Cairo (EG)
Publication Details
- Journal
- Current Gene Therapy
- Published
- 2025-02-20
- DOI
- https://doi.org/10.2174/0115665232332419250213081510
- Citations
- 6
- Primary Topic
- Studies on Chitinases and Chitosanases
- Type
- article
- Field-Weighted Citation Impact
- 4.84